1-(3-吡啶)乙胺 | 56129-55-6

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 1-(3-吡啶)乙胺
• 中文别名: 1-(3-吡啶基)乙胺
• 英文名称: 1-pyridin-3-yl-ethylamine
• 英文别名: 1-(pyridin-3-yl)ethan-1-amine；1-pyridin-3-ylethanamine
• CAS: 56129-55-6
• 化学式: C₇H₁₀N₂
• mdl: MFCD01691641
• 分子量: 122.17
• InChiKey: IQVQNBXPYJGNEA-UHFFFAOYSA-N

物化性质

• 熔点：
  63 °C
• 沸点：
  118-120 °C(Press: 14 Torr)
• 密度：
  1.014 g/cm3(Temp: 25 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  8
• 危险品标志：
  Xi,T
• 海关编码：
  2933399090
• 包装等级：
  III
• WGK Germany：
  3
• 危险品运输编号：
  UN2735
• 危险类别：
  8
• 危险性防范说明：
  P264,P271,P280,P301+P330+P331,P303+P361+P353,P304+P340,P305+P351+P338,P310,P363,P403+P233,P501
• 危险性描述：
  H314
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
1-Pyridin-3-yl-ethylamine
Product Name:
Synonyms: 3-(1-Aminoethyl)pyridine

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H301: Toxic if swallowed
H315: Causes skin irritation
H318: Causes serious eye damage
H335: May cause respiratory irritation
Avoid breathing dust/fume/gas/mist/vapours/spray
P261:
P280: Wear protective gloves/protective clothing/eye protection/face protection
P301+P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
1-Pyridin-3-yl-ethylamine
Ingredient name:
CAS number: 56129-55-6

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H10N2
Molecular weight: 122.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
UN Number: UN2811 Class: 6.1 Packing group: III
Proper shipping name: TOXIC SOLIDS, ORGANIC, N.O.S. (1-Pyridin-3-yl-ethylamine)

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(3-吡啶)乙胺 在 palladium 10% on activated carbon 氢气 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 、 氯仿 为溶剂， 20.0 ℃ 、344.75 kPa 条件下， 反应 4.0h， 生成
  参考文献：
  名称：

  WO2008/85505

  摘要：

  公开号：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 乙醇 、 溶剂黄146 、 锌 作用下， 生成 1-(3-吡啶)乙胺
  参考文献：
  名称：

  La Forge, Journal of the American Chemical Society, 1928, vol. 50, p. 2482

  摘要：

  DOI：

文献信息

• Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
  申请人：——

  公开号：US20030166644A1

  公开（公告）日：2003-09-04

  Use of compounds to inhibit hormone-sensitive lipase, pharmaceutical compositions comprising the compounds, methods of treatment employing these compounds and compositions, and novel compounds. The present compounds are inhibitors of hormone-sensitive lipase and may be useful in the treatment and/or prevention of medical disorders where a decreased activity of hormone-sensitive lipase is desirable.

  使用化合物抑制激素敏感性脂肪酶，包括这些化合物的药物组合物，使用这些化合物和组合物的治疗方法，以及新化合物。目前的化合物是激素敏感性脂肪酶的抑制剂，可能在治疗和/或预防需要降低激素敏感性脂肪酶活性的医学疾病中有用。
• [EN] AZAINDOLE DERIVATIVES WHICH ACT AS PI3K INHIBITORS<br/>[FR] DÉRIVÉS D'AZAINDOLE AGISSANT COMME INHIBITEUR DE PI3K
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2014011568A1

  公开（公告）日：2014-01-16

  Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating immunological disorders, cardiovascular disease, cancer, and other diseases, disorders or conditions associated with PI3Kδ.

  揭示了Formula 1的化合物及其药用盐，其中R1、R2、R3、R4、R5、R6、R7、R8、R9和R10在规范中有定义。本公开还涉及制备Formula 1化合物的材料和方法，含有它们的药物组合物，以及它们用于治疗免疫性疾病、心血管疾病、癌症和与PI3Kδ相关的其他疾病、疾患或症状的用途。
• HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS
  申请人：CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD.

  公开号：US20170253614A1

  公开（公告）日：2017-09-07

  A series of hepatitis C virus (HCV) inhibitors and compositions and applications thereof in the preparation of drugs for treating chronic HCV infection. Especially, a series of compounds that are used as NS5A inhibitors, and compositions and uses thereof in the preparations of drugs.

  一系列丙型肝炎病毒（HCV）抑制剂及其组合物，以及在制备用于治疗慢性HCV感染的药物时的应用。特别是一系列用作NS5A抑制剂的化合物，以及在药物制剂中的组合物和用途。
• Src kinase inhibitor compounds
  申请人：Merck & Co., Inc.

  公开号：US06498165B1

  公开（公告）日：2002-12-24

  Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and treatment of protein tyrosine kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogensis, atheroscelerosis, graft rejection, rheumatoid arthritis and psoriasis.

  嘧啶化合物（化学式I），或其药用可接受的盐、水合物、溶剂合物、晶型和单一对映异构体，以及包括这些化合物的药物组合物，它们是酪氨酸激酶酶的抑制剂，因此在预防和治疗蛋白酪氨酸激酶相关疾病方面具有用处，如免疫疾病、高增殖性疾病和其他认为不当的蛋白激酶作用可能起作用的疾病，如癌症、血管生成、动脉粥样硬化、移植排斥、类风湿性关节炎和牛皮癣。
• General and selective synthesis of primary amines using Ni-based homogeneous catalysts
  作者：Kathiravan Murugesan、Zhihong Wei、Vishwas G. Chandrashekhar、Haijun Jiao、Matthias Beller、Rajenahally V. Jagadeesh

  DOI：10.1039/d0sc01084g

  日期：——

  Ni-triphos complex as the first Ni-based homogeneous catalyst for both reductive amination of carbonyl compounds with ammonia and hydrogenation of nitroarenes to prepare all kinds of primary amines. Remarkably, this Ni-complex enabled the synthesis of functionalized and structurally diverse benzylic, heterocyclic and aliphatic linear and branched primary amines as well as aromatic primary amines starting

  通过应用丰富且原子经济的试剂来开发用于工业上相关的胺化和氢化反应的贱金属催化剂，对于经济高效且可持续地合成代表非常重要的化学物质的胺而言，仍然至关重要。尤其是，伯胺的合成至关重要，因为这些化合物用作生产增值精细化学品和散装化学品以及药品，农用化学品和原料的关键前体和主要中间体。在这里，我们报道了一种Ni-triphos络合物，它是第一个用于镍的羰基化合物与氨的还原胺化和硝基芳烃加氢制备各种伯胺的Ni基均相催化剂。值得注意的是，这种镍配合物可以合成功能化且结构多样的苄基，杂环和脂肪族直链和支链伯胺以及芳香族伯胺，是使用氨和分子氢从廉价且易于获得的羰基化合物（醛和酮）和硝基芳烃开始的。这种镍催化的还原胺化方法已用于胺化更复杂的药物和类固醇衍生物。已经对基于Ni-triphos的还原胺化反应进行了详细的DFT计算，结果表明整个反应具有H的内球机理。这种镍催化的还原胺化方法已用于胺化更复杂的药物和